As the field of targeted therapeutics continues to evolve, developers face increasing complexity in designing bioconjugates that meet both scientific and manufacturing requirements. From antibody-drug conjugates (ADCs) and radioconjugates to imaging agents and next-generation targeted therapies, successful development requires careful coordination of multiple variables—from conjugation chemistry and linker architecture to payload selection, analytical characterization, and scale-up planning.
To help address these challenges, Xcellon Biologics has announced the launch of XSpec™, its proprietary Bioconjugation Configurator designed to streamline the early planning and evaluation process for bioconjugation programs.
The online platform enables biotechnology companies, pharmaceutical developers, and research organizations to rapidly define key program parameters and receive expert scientific feedback before entering development.
Bringing Structure to a Complex Process
Bioconjugation development involves a series of interconnected decisions that can significantly impact a program’s success. Selecting the appropriate modality, determining the optimal conjugation strategy, evaluating linker-payload combinations, and planning analytical characterization all play critical roles in achieving the desired product profile.
XSpec™ was developed to simplify this process by guiding users through a structured evaluation of their program requirements.
Through the configurator, users can:
- Select optimal conjugate modalities for therapeutic or imaging applications
- Evaluate conjugation chemistries based on biological and chemical requirements
- Define linker architecture, payload class, and target Drug-to-Antibody Ratio (DAR)
- Explore advanced development approaches, including dual-payload and bioorthogonal strategies
- Specify batch scale, formulation needs, and development objectives
- Build customized analytical and in vitro characterization packages appropriate for their stage of development
Following submission, the Xcellon scientific team conducts a comprehensive feasibility assessment covering chemistry, manufacturability, timelines, and expected deliverables.
Accelerating Development Through Scientific Partnership
According to Xcellon, one of the platform’s key advantages is speed. Organizations that submit a configuration through XSpec™ can expect engagement from an Xcellon scientist within 48 hours to review project requirements and discuss potential development pathways.
Throughout project execution, clients receive ongoing progress updates, analytical data packages, and technical support. Final deliverables include fully characterized conjugates accompanied by supporting documentation such as Certificates of Analysis (CoA), DAR distribution data, SEC/HIC chromatograms, and comprehensive project reports.
Supporting the Future of Bioconjugation
The launch of XSpec™ reflects Xcellon Biologics’ broader mission to build a Contract Research, Development, and Manufacturing Organization (CRDMO) focused specifically on the growing needs of the bioconjugation sector.
As demand increases for more sophisticated targeted therapeutics, developers require partners capable of supporting every stage of the process—from linker-payload design and site-specific conjugation to analytical characterization and manufacturing readiness.
With XSpec™, Xcellon aims to provide innovators with a more efficient path from concept to development while reducing uncertainty during early-stage program planning.
Organizations interested in exploring bioconjugation strategies can access the XSpec™ Bioconjugation Configurator and connect directly with Xcellon’s scientific team to discuss project requirements and development opportunities.
Learn More
Bioconjugation Configuration Tool:https://xcellon.bio/bioconjugation-configuration/
About Xcellon
Xcellon Biologics is a highly specialized CDMO focused on complex biologics including Antibody Drug Conjugates (ADCs), Bioconjugates, Bispecific Antibodies, and T-Cell Engagers.
